MBF Therapeutics Inc. to present at Philadelphia PACT Investor Conference
October 30, 2017 – Ambler, PA – MBF Therapeutics, Inc. a clinical stage animal health company developing checkpoint inhibitor vaccines for cancer and infectious diseases, today announced that Thomas Tillett, Chief Executive Officer, will present at the PACT Capital Conference in Philadelphia, PA on Thursday, November 2, 2017 at 9:45am EDT.
To view a full copy of the presentation click HERE
About MBF Therapeutics: MBFT (www.mbftherapeutics.com) MBFT is a clinical-stage animal health company developing and commercializing proprietary checkpoint inhibitor immunotherapy technology for cancer and infectious diseases. T-cell activation precisely targets selected antigens associated with cancer cells or infectious pathogens while preventing T-cell exhaustion, thus, yielding a durable cell-mediated immunity. Exclusively licensed from the Wistar Institute in Philadelphia, PA, and combined with a proprietary nonviral delivery system, this is a platform technology from which multiple innovative products can be developed for veterinary use where cellular antigens are well defined.